NF279: a novel potent and selective antagonist of P2X receptor-mediated responses.

  title={NF279: a novel potent and selective antagonist of P2X receptor-mediated responses.},
  author={Steven Damer and B Niebel and S Czeche and Peter Nickel and Ursula Ardanuy and Guenther Schmalzing and J{\"u}rgen Rettinger and Ernst Mutschler and G{\"u}nter Lambrecht},
  journal={European journal of pharmacology},
  volume={350 1},
8,8'-(Carbonylbis(imino-4, 1 -phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis(1,3, 5-naphthalenetrisulfonic acid) (NF279) antagonized P2X receptor-mediated contractions in rat vas deferens, evoked by alpha,beta-methylene ATP (10 microM; pIC50=5.71) without affecting responses mediated via alpha1A-adrenoceptors, adenosine A1 and A2B receptors, histamine H1, muscarinic M3 and nicotinic receptors. The low inhibitory potency of NF279 on P2Y receptors in guinea-pig taenia coli (pA2=4.10) and… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 22 extracted citations

Purinergic dysregulation in pulmonary hypertension.

American journal of physiology. Heart and circulatory physiology • 2016
View 8 Excerpts
Highly Influenced

P2X receptors as drug targets.

Molecular pharmacology • 2013
View 2 Excerpts

Similar Papers

Loading similar papers…